DDX53 and neoplasm: Compared with CT26/WT, CT26/SCID tumor lysates could significantly suppress tumor growth, increase CD3+ tumor-infiltrating lymphocytes (TILs), enhance CTL functions, and trigger Th-1 predominant immune responses.